Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer

International Journal of Clinical Oncology · Published 2026-06-25 · DOI 10.1007/s10147-026-03102-2

Free full text

Authors (9)

Neal Shore, Nguyen, Barinder Kang, Amrita Sawhney, Clare Byrne, Jackson Tang, Magdaliz Gorritz, Chi-Chang Chen, Jeetvan Patel

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shore, N., Nguyen, Kang, B., et al. (2026). Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-026-03102-2

Related articles

• Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis · International Journal of Clinical Oncology · 2026 · Same journal
• Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study · International Journal of Clinical Oncology · 2026 · Same journal
• The role of surgical timing in survival of patients with spinal metastases · International Journal of Clinical Oncology · 2026 · Same journal
• Racial disparities in time to treatment initiation and survival outcomes in patients with vulvar cancer: a national cancer database analysis · International Journal of Clinical Oncology · 2026 · Same journal
• Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testing · International Journal of Clinical Oncology · 2026 · Same journal
• Positive peritoneal cytology and recurrence patterns in endometrial cancer according to postoperative recurrence risk classification: a retrospective cohort study · International Journal of Clinical Oncology · 2026 · Same journal
• Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma · International Journal of Clinical Oncology · 2026 · Same journal
• Prognostic significance of predicted skeletal muscle index after curative-intent resection for non-small cell lung cancer · International Journal of Clinical Oncology · 2026 · Same journal
• RNF125 mediates the anti-breast cancer activity of betulinic acid through ubiquitin-dependent degradation of MYH9 · International Journal of Clinical Oncology · 2026 · Same journal
• Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy · International Journal of Clinical Oncology · 2026 · Same journal